Prophylactic recombinant factor VIIa administration to an infant with congenital systemic juvenile xanthogranuloma

Paediatric Anaesthesia

Volumn 16, Issue 9, 2006, Pages 974-976

  De Santiago, Jesus ^a   Martinez Garcia, Ernesto ^a   Giron, Jorge ^a   Salcedo, Concepción ^a   Pérez Gallardo, Antonio ^a  

^a HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

Author keywords

Congenital systemic juvenile xanthogranuloma; Recombinant factor VIIa; Recombinant activated factor VIIa; Refractory coagulopathy

Indexed keywords

CYTARABINE; FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 7A; VINBLASTINE;

ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BONE MARROW BIOPSY; CASE REPORT; CENTRAL VENOUS CATHETER; FEMALE; HUMAN; IMPLANTATION; INFANT; INFUSION; JUVENILE XANTHOGRANULOMA; LIVER BIOPSY; LIVER DYSFUNCTION; PRIORITY JOURNAL; PROPHYLAXIS; REFRACTORY THROMBOCYTOPENIA; THROMBOCYTE TRANSFUSION;

FACTOR VIIA; FEMALE; HEMORRHAGE; HUMANS; INFANT, NEWBORN; RECOMBINANT PROTEINS; XANTHOGRANULOMA, JUVENILE;

EID: 33747036688     PISSN: 11555645     EISSN: 14609592     Source Type: Journal    
DOI: 10.1111/j.1460-9592.2006.02009.x     Document Type: Article

References (15)

1. Favara BE, Feller AC, Pauli M et al. Contemporary classification of histiocytic disorders. The WHO Committee on Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol 1997; 29: 157-166.
2. Dehner LP. Juvenile xanthogranuloma in the first two decades of life. Am J Surg Pathol 2003; 27: 579-593.
3. Freyer DR, Kennedy R, Bostrom BC et al. Juvenile xanthogranuloma: forms of systemic disease and their clinical implications. J Pediatr 1996; 129: 227-237.
4. Rutherford CJ, Frenkel EP. Hemostatic disorders in liver disease. In: Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff's Diseases of the Liver, 8th ed. Philadelphia: Lippincott Williams & Wilkins, 1999: 583-598.
5. Silva MA, Muralidharan V, Mirza DF. The management of coagulopathy and blood loss in liver surgery. Semin Hematol. 2004; 41(1 Suppl. 1): 132-139 (Review).
6. Brown JB, Emerick KM. Recombinant factor VIIa improves coagulopathy caused by liver failure. J Pediatr Gastroenterol Nutr. 2003; 37: 268-272.
7. Chuansumrit A, Treepongkaruna S, Phuapradit P. Combined fresh frozen plasma with recombinant factor VIIa in restoring hemostasis for invasive procedures in children with liver diseases. Thromb Haemost 2001; 85: 748-749.
8. Kristensen J, Killander A, Hippe E et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis 1997; 26 (Suppl.): 159-164.
9. Poon MC, Demers C, Jobin F et al. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 1999; 94: 3951-3953.
10. Goodnough LT. Experiences with recombinant human factor VIIa in patients with thrombocytopenia. Semin Hematol. 2004; 41(1 Suppl. 1): 25-29.
11. Hedner U. Mechanism of action of recombinant activated factor VII: an update. Semin Hematol. 2006; 43(1 Suppl. 1): S105-S107.
12. Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2: 899-909.
13. Pusateri A, Park M. Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma. Critical Care 2005; 9(Suppl. 5): S15-S24.
14. Cid AR, Lorenzo JI, Haya S et al. A comparison of FVII:C and FVIIa assays for the monitoring of recombinant factor VIIa treatment. Haemophilia. 2001; 7: 39-41.
15. Green G, Poller L, Thomson JM et al. Factor VII as a marker of hepatocellular synthetic function in liver disease. J Clin Pathol 1976; 29: 971-975.